Former Chief Financial Officer Brings 30 Years of Business
Leadership and Board of Directors’ Experience

December 14, 2015 08:00 AM Eastern Daylight Time

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Intellia Therapeutics, Inc., a leading gene-editing company, has named
Caroline Dorsa to its Board of Directors. Both as a director and
business leader, Ms. Dorsa brings over 30 years of diverse experience
and management in the public sector and regulated industries, including
energy, pharmaceuticals and telecommunications.

“I am pleased to join Intellia’s Board of Directors and to help advance
the company’s mission of developing therapeutics utilizing CRISPR/Cas9
gene-editing technology”

Ms. Dorsa has held a number of senior-management positions at Merck &
Co., Inc., including Vice President and Treasurer where she also oversaw
tax, financial planning for manufacturing and investor relations. Most
recently, as Executive Vice President and CFO at Public Service
Enterprise Group, Ms. Dorsa led the finance, business development and
investor relations teams, delivering solid financial performance through
a challenging period in the energy markets. She is a director of Biogen
Inc.

“We are excited to have Caroline join our Board of Directors at such an
important stage in Intellia’s growth and during the rapid acceleration
of the gene-editing industry,” says Nessan Bermingham, Ph.D., Founder
and Chief Executive Officer, Intellia Therapeutics. “We are fortunate to
benefit from her extensive board and business experience, particularly
in finance, corporate governance, risk management and compensation, as
we grow a sustainable company with transformational treatments for
patients.”

“I am pleased to join Intellia’s Board of Directors and to help advance
the company’s mission of developing therapeutics utilizing CRISPR/Cas9
gene-editing technology,” says Caroline Dorsa, member of board of
directors, Intellia Therapeutics. “The Intellia team is extraordinarily
committed and aligned on the path to bring potential cures to patients.”

About Intellia Therapeutics

Intellia Therapeutics is a leading gene-editing company focused on the
development of proprietary products utilizing the recently discovered
CRISPR/Cas9 technology. Intellia intends to advance its pipeline and
potentially develop a new drug class by leveraging its leading
scientific and clinical development expertise and its exclusive access
to one of the most comprehensive intellectual property platforms
available. Intellia is supported by its founding investors Atlas and
Novartis, as well a number of public and private sector funds. In 2014,
Intellia was named as one of the top 10 biotech start-ups by Nature
Biotechnology. In September 2015, Intellia was named a “Fierce 15”
biotech company by FierceBiotech. Learn more about Intellia
Therapeutics and CRISPR/Cas9 at intelliatx.com;
Follow us on Twitter @intelliatweets.